Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Promissory Note: Dated 2024-08-09 for $ 549,280.00
With 550K warrants @ $1.03 expire, 2029-0-09
Out of Alberta (Accredited Investor)
Koo